JP2010538010A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010538010A5 JP2010538010A5 JP2010523136A JP2010523136A JP2010538010A5 JP 2010538010 A5 JP2010538010 A5 JP 2010538010A5 JP 2010523136 A JP2010523136 A JP 2010523136A JP 2010523136 A JP2010523136 A JP 2010523136A JP 2010538010 A5 JP2010538010 A5 JP 2010538010A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- steroid
- isomers
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 239000000812 cholinergic antagonist Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003172 expectorant agent Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 229940066491 mucolytics Drugs 0.000 claims 2
- 239000003149 muscarinic antagonist Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 206010006482 Bronchospasm Diseases 0.000 claims 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical group [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 claims 1
- 102000003816 Interleukin-13 Human genes 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 1
- 229960004308 acetylcysteine Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000006242 amine protecting group Chemical group 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 229960003121 arginine Drugs 0.000 claims 1
- 229940092705 beclomethasone Drugs 0.000 claims 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 230000007885 bronchoconstriction Effects 0.000 claims 1
- 229960004436 budesonide Drugs 0.000 claims 1
- ZNEWHQLOPFWXOF-UHFFFAOYSA-N coenzyme M Chemical compound OS(=O)(=O)CCS ZNEWHQLOPFWXOF-UHFFFAOYSA-N 0.000 claims 1
- 229940109248 cromoglycate Drugs 0.000 claims 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical group O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229960000676 flunisolide Drugs 0.000 claims 1
- 229960002714 fluticasone Drugs 0.000 claims 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 1
- 229940015042 glycopyrrolate Drugs 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229940047122 interleukins Drugs 0.000 claims 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical group O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 claims 1
- 229960001888 ipratropium Drugs 0.000 claims 1
- 229960001664 mometasone Drugs 0.000 claims 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000000770 proinflammatory effect Effects 0.000 claims 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims 1
- 229940110309 tiotropium Drugs 0.000 claims 1
- 229960005294 triamcinolone Drugs 0.000 claims 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96643807P | 2007-08-28 | 2007-08-28 | |
| US60/966,438 | 2007-08-28 | ||
| PCT/US2008/074653 WO2009032764A1 (en) | 2007-08-28 | 2008-08-28 | Acetamide stereoisomer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010538010A JP2010538010A (ja) | 2010-12-09 |
| JP2010538010A5 true JP2010538010A5 (enExample) | 2013-08-15 |
| JP5468543B2 JP5468543B2 (ja) | 2014-04-09 |
Family
ID=40291128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010523136A Expired - Fee Related JP5468543B2 (ja) | 2007-08-28 | 2008-08-28 | アセトアミド立体異性体 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US8501994B2 (enExample) |
| EP (1) | EP2195285B1 (enExample) |
| JP (1) | JP5468543B2 (enExample) |
| KR (1) | KR101398775B1 (enExample) |
| AR (1) | AR072943A1 (enExample) |
| AU (1) | AU2008296458B2 (enExample) |
| CA (1) | CA2696943C (enExample) |
| ES (1) | ES2684125T3 (enExample) |
| MX (1) | MX2010001978A (enExample) |
| NZ (1) | NZ583462A (enExample) |
| TW (1) | TWI505826B (enExample) |
| WO (1) | WO2009032764A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200510277A (en) * | 2003-05-27 | 2005-03-16 | Theravance Inc | Crystalline form of β2-adrenergic receptor agonist |
| US8501994B2 (en) | 2007-08-28 | 2013-08-06 | Sunovion Pharmaceuticals Inc. | Acetamide stereoisomer |
| EP2578570A1 (en) | 2011-10-07 | 2013-04-10 | Almirall, S.A. | Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis. |
| EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
| AU2020224153B2 (en) * | 2019-02-22 | 2025-03-06 | Cila Therapeutic Inc. | Inhalable therapeutic agent |
| CN111944855B (zh) * | 2020-09-03 | 2022-08-30 | 扬州中宝药业股份有限公司 | 一种合成(r)-1-(4-(苄氧基)-3-硝基苯基)-2-溴乙醇的方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1415256A (en) | 1972-02-05 | 1975-11-26 | Yamanouchi Pharma Co Ltd | Alpha-aminomethylbenzyl alcohol derivatives |
| DE2366625C2 (enExample) | 1972-02-05 | 1988-06-09 | Yamanouchi Pharmaceutical Co., Ltd., Tokio/Tokyo, Jp | |
| US3994974A (en) * | 1972-02-05 | 1976-11-30 | Yamanouchi Pharmaceutical Co., Ltd. | α-Aminomethylbenzyl alcohol derivatives |
| JPS4880523A (enExample) * | 1972-02-05 | 1973-10-29 | ||
| JPS599542B2 (ja) * | 1980-06-11 | 1984-03-03 | 山之内製薬株式会社 | 新規な３−アシルアミノ−４−ヒドロキシ−α−（アラルキルアミノメチル）ベンジルアルコ−ルの製法 |
| ES2005492A6 (es) | 1987-12-23 | 1989-03-01 | Lasa Lab | Procedimiento de obtencion de n-(2-hidroxi-5-(1-hidroxi-2((2- (4-metoxifenil)-1metiletil)amino)etil)fenil)foramida (i). |
| ES2031407A6 (es) | 1988-10-05 | 1992-12-01 | Lasa Lab | Mejoras introducidas en el objeto de la patente principal n{ 8703715 por: procedimiento de obtencion de n-(2-hidroxi-5-(1-hidroxi-2-((2-(4-metoxifenil)-1-metiletil)amino)etil)fenil)formamida". |
| EP0882707B1 (en) | 1996-01-10 | 2003-10-08 | Asahi Kasei Kabushiki Kaisha | Novel tricyclic compounds and drug compositions containing the same |
| WO1998021175A1 (en) | 1996-11-11 | 1998-05-22 | Sepracor, Inc. | Process for the preparation of optically pure isomers of formoterol |
| US6040344A (en) * | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
| US6303145B2 (en) * | 1999-05-10 | 2001-10-16 | Sepracor Inc. | (S,R) formoterol methods and compositions |
| US6472563B1 (en) * | 2001-11-09 | 2002-10-29 | Sepracor Inc. | Formoterol tartrate process and polymorph |
| US7718822B2 (en) * | 2007-08-28 | 2010-05-18 | Sepracor Inc. | Carbamate Stereoisomer |
| US8501994B2 (en) * | 2007-08-28 | 2013-08-06 | Sunovion Pharmaceuticals Inc. | Acetamide stereoisomer |
-
2008
- 2008-08-22 US US12/196,520 patent/US8501994B2/en not_active Expired - Fee Related
- 2008-08-26 TW TW097132495A patent/TWI505826B/zh not_active IP Right Cessation
- 2008-08-27 AR ARP080103726A patent/AR072943A1/es unknown
- 2008-08-28 JP JP2010523136A patent/JP5468543B2/ja not_active Expired - Fee Related
- 2008-08-28 KR KR1020107006647A patent/KR101398775B1/ko not_active Expired - Fee Related
- 2008-08-28 EP EP08829102.6A patent/EP2195285B1/en not_active Not-in-force
- 2008-08-28 WO PCT/US2008/074653 patent/WO2009032764A1/en not_active Ceased
- 2008-08-28 NZ NZ583462A patent/NZ583462A/en not_active IP Right Cessation
- 2008-08-28 ES ES08829102.6T patent/ES2684125T3/es active Active
- 2008-08-28 MX MX2010001978A patent/MX2010001978A/es active IP Right Grant
- 2008-08-28 CA CA2696943A patent/CA2696943C/en active Active
- 2008-08-28 AU AU2008296458A patent/AU2008296458B2/en not_active Ceased
-
2013
- 2013-07-03 US US13/934,996 patent/US8664441B2/en active Active
-
2014
- 2014-01-17 US US14/157,793 patent/US9040588B2/en active Active
-
2015
- 2015-04-22 US US14/692,843 patent/US9499476B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019038818A (ja) | 医薬組成物 | |
| JP2010538010A5 (enExample) | ||
| JP2018199684A5 (enExample) | ||
| JP2008501705A5 (enExample) | ||
| JP2017526716A5 (enExample) | ||
| JP2010518122A5 (enExample) | ||
| JP2013531056A5 (enExample) | ||
| JP2016516020A5 (enExample) | ||
| JP2014502641A5 (enExample) | ||
| JP2004526788A5 (enExample) | ||
| PE20091672A1 (es) | Nueva dosificacion y formulacion | |
| RU2013106866A (ru) | Фармацевтические композиции | |
| AU2008241045B2 (en) | Use of a composition comprising formoterol and beclometasone dipropionate for the prevention and/or treatment of an exacerbation of asthma | |
| JP2016510785A5 (enExample) | ||
| US20130189319A1 (en) | Methods and compositions for administration of oxybutynin | |
| AR072943A1 (es) | Estereo isomero de metil-(2-hidroxi-5-(((2-(4-hidroxifenil)-1-metiletil)amino)etil)fenil)-acetamida, mezcla de sus isomeros, proceso de preparacion del mismo, una composicion farmaceutica que contiene a dicho carbamato y uso del mismo | |
| JP2006501207A5 (enExample) | ||
| JP2011500731A5 (enExample) | ||
| JP2013518061A5 (enExample) | ||
| US20170119744A1 (en) | Pharmaceutical Composition Comprising a Beta-2-Agonist and Anticholinergic Agent | |
| AU2013368298B2 (en) | Methods and compositions for administration of oxybutynin | |
| US20190224164A1 (en) | Compositions and methods for treatment of copd | |
| FI4188327T3 (fi) | Yhdistelmähoito inhalaatioannosteluun | |
| JP2016533323A5 (enExample) | ||
| HK1137357B (en) | Use of a composition comprising formoterol and beclometasone dipropionate in the manufacture of a pharmaceutical for the prevention and/or treatment of an exacerbation of asthma |